MedCity News June 23, 2021
Messenger RNA therapies are coming in many forms and Strand Therapeutics is developing “next generation” treatments that can be programmed with features and functions, similar to how software code is written. Led by CEO Jacob Becraft, the startup has raised $52 million to support its R&D.
Messenger RNA brought the world its first Covid-19 vaccines, demonstrating along the way how this technology works. Strand Therapeutics is developing what could become the next generation of mRNA products: genetic circuits programmed with various features and functions, similar to the way writing computer code tells software how to execute multiple tasks. Already partnered with a large pharmaceutical company, the startup now has $52 million to bring its first programmable mRNA therapy into the...
Today's Sponsors
Today's Sponsor